Mar 25th 2013 - Edison Investment Research today published a report on Acal (ACL.L, LSE:ACL, LON:ACL) entitled "A HyACT To Follow". In summary, the report says:
Alchemia’s c 60% share price decline after the failed spin-out of its oncology division, Audeo, belies a promising late stage cancer candidate incorporating the company’s HyACT drug delivery platform. A Phase III trial of Audeo’s lead product HA-Irinotecan versus conventional irinotecan as part of the FOLFIRI regime in second/third line metastatic colorectal cancer is fully recruited and should read out results in early 2014. Favourable data may pave the way for US approval in 2015 and validate the HyACT platform (in which drugs are co-formulated with hyaluronic acid) for use with other chemotherapeutic agents.
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »